 RANCHO CUCAMONGA, Calif., May 03, 2021 GLOBE NEWSWIRE -- Amphastar Pharmaceuticals, Inc. NASDAQ: AMPH announced that the U.S. Food and Drug Administration FDA approved the Companys Abbreviated New Drug Application ANDA for Morphine Sulfate injection 1mgmL in the 30mL Pump-Jet Prefilled Syringe System. It is indicated for the management of pain severe enough to require use of an opioid analgesic by Patient-Controlled Analgesia PCA, only for use with a compatible Alaris infusion device, and for which alternative treatments are inadequate. For the past 30 years, the company has sold and marketed the product under the grandfather exception to the FDAs Prescription Drug Wrap-Up program. Net revenues for the Companys Morphine injection for the year ended December 31, 2020, were 2.3 million. 